Bernstein Maintains a Hold on Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best large cap value stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) without assigning a price target.

How Bristol-Myers Squibb Company (BMY) Delivers Strong Yields Even in Tough Markets

Bristol-Myers Squibb Company (NYSE:BMY) reported $12.3 billion in revenues in fiscal Q2 2025, with growth portfolio revenues of $6.6 billion, up 18%.

GAAP EPS for the quarter was $0.64, and non-GAAP EPS was $1.46.

Bristol-Myers Squibb Company (NYSE:BMY) also raised its 2025 revenue guidance to the range of ~$46.5 billion to $47.5 billion, and updated its non-GAAP EPS range to $6.35 to $6.65.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.